Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/ejhf.1860
PubMed Identifier: 32452085
Publication URI: http://europepmc.org/abstract/MED/32452085
Type: Journal Article/Review
Volume: 22
Parent Publication: European journal of heart failure
Issue: 8
ISSN: 1388-9842